 |
 |
|
"Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference"
Date: November 25, 2008
Client: Anadys Pharmaceuticals
|
|
|
|
 |
|
"EntreMed to Present at the New York Society of Security Analysts Industry Conference"
Date: November 25, 2008
Client: EntreMed
|
|
|
|
 |
|
"Helix BioPharma Files Form 20-F Registration Statement With The U.S. Securities and Exchange Commission"
Date: November 25, 2008
Client: Helix BioPharma
|
|
|
|
 |
|
"Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma"
Date: November 25, 2008
Client: Light Sciences Oncology
|
|
|
|
 |
|
"Clinic Roundup"
Date: November 21, 2008
Client: Cougar Biotechnology
Summary: Cougar Biotechnology Inc., of Los Angeles, reported first patient enrollment in a Phase I/II trial of its drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/ C17,20 lyase, in advanced breast cancer.
|
|
|
|
 |
|
"Cougar initiates Ph I/II CB7630 trial"
Date: November 21, 2008
Client: Cougar Biotechnology
Summary: California, USA-based Cougar Biotechnology says that the first patient was enrolled in a Phase I/II clinical trial of its drug candidate CB7630 (abiraterone acetate), an orally-active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced breast cancer.
|
|
|
|
 |
|
"Vical Announces Strategic Restructuring and Staff Reduction"
Date: November 21, 2008
Client: Vical
|
|
|
|
 |
|
"Cougar Biotechnology initiates enrollment in Phase I/II breast cancer study"
Date: November 21, 2008
Client: Cougar Biotechnology
Summary: Cougar Biotechnology has enrolled the first patient in a Phase I/II clinical trial of the company's drug candidate CB7630, an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced breast cancer.
|
|
|
|
 |
|
"Leading European providers of innovative Minimally Invasive Biopsy devices enter into a cooperative distribution agreement for the US market"
Date: November 21, 2008
Client: Radi Medical Systems
|
|
|
|
|
|
Date: November 21, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, of Lausanne, Switzerland, licensed exclusive ex-Asia rights to Debio 0617 from Bangalore, India-based Aurigene Discovery Technologies Ltd. Debiopharm will pay Aurigene an undisclosed upfront fee and milestone payments.
|
|
|
|
 |
|
"Cougar Biotechnology Inc - CGRB: Begins Enrollment for Ph I/II Trial of CB7630 in Advanced Breast Cancer" - Fain Hughes
Date: November 20, 2008
Client: Cougar Biotechnology
Summary: Cougar Biotechnology, Inc. (CGRB) announced that the first patient was enrolled in a Phase I/II clinical trial of the Company's drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced breast cancer.
|
|
|
|
 |
|
"Cougar starts Phase I/II Trial of CB7630 in advanced breast cancer patients"
Date: November 20, 2008
Client: Cougar Biotechnology
Summary: US-based development-stage biopharmaceutical company Cougar Biotechnology Inc (NASDAQ: CGRB) it has enrolled the first patient in a Phase I/II clinical trial of its drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced breast cancer.
|
|
|
|
 |
|
"Aurigene to Assist with Advancement of Debiopharm's Oncology Compound"
Date: November 20, 2008
Client: Debiopharm Group
Summary: Debiopharm Group and Aurigene Discovery Technologies signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialize Debio 0617, an inhibitor of an undisclosed oncology pathway.
|
|
|
|
|
|
"Debiopharm, Aurigene sign licensing agreement"
Date: November 20, 2008
Client: Debiopharm Group
Summary: Switzerland-headquartered biopharmaceutical company Debiopharm Group and a India-based biotechnology firm Aurigene Discovery Technologies Ltd, announced today (20 November) that they have signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialise Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
|
|
|
|
 |
|
"Febit signs technology development agreement with In-Q-Tel"
Date: November 20, 2008
Client: febit
Summary: Febit group, a provider of advanced and flexible genomic analysis solutions, has signed a strategic investment and technology development agreement with In-Q-Tel, a not-for-profit investment firm that delivers technology solutions.
|
|
|
|
|
|
"febit biotech signs technology development agreement with In-Q-Tel"
Date: November 20, 2008
Client: febit
Summary: febit biotech gmbh (formerly febit ag), a Germany-based biotechnology company, has announced an investment and technology development agreement with In-Q-Tel, Inc., a US-based not-for-profit investment firm, for the development of febit's Geniom(R) technology to detect pathogens more quickly and with increased reliability.
|
|
|
|
|
|
"Debiopharm licenses Debio 0617 to Aurigene"
Date: November 20, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, a Swiss biopharmaceutical firm, has signed a worldwide license agreement excluding Japan and the rest of Asia to develop and commercialize Debio 0617 with Indian firm Aurigene Discovery Technologies.
|
|
|
|
 |
|
"Debiopharm and Aurigene sign licensing agreement"
Date: November 20, 2008
Client: Debiopharm Group
Summary: Debiopharm Group - a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology - and Aurigene Discovery Technologies Ltd - a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates - signed an exclusive worldwide license agreement, to develop and commercialise Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
|
|
|
|
 |
|
"Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway"
Date: November 20, 2008
Client: Debiopharm Group
|
|
|
|
 |
|
"Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer Patients"
Date: November 20, 2008
Client: Cougar Biotechnology
|
|
|
|
 |
|
"febit Announces Strategic Investment and Technology Development Agreement with In-Q-Tel"
Date: November 19, 2008
Client: febit
|
|
|
|
|
|
"Helix BioPharma Presents Preclinical L-DOS47 Data at the Second Conference of Lung Cancer in Warsaw Poland"
Date: November 19, 2008
Client: Helix BioPharma
|
|
|
|
|
|
"In-Q-Tel Invests in Development of febit's Biosecurity Platform"
Date: November 19, 2008
Client: febit
Summary: febit group reported a strategic investment and technology development agreement with In-Q-Tel, which will facilitate further development of the company's Geniom ® Technology to detect pathogens.
|
|
|
|
 |
|
"Febit Inks Biosecurity Development Deal with In-Q-Tel"
Date: November 19, 2008
Client: febit
Summary: Febit signed a strategic investment and technology development agreement with In-Q-Tel to further develop Febit's Geniom technology for biosecurity applications. The firms expect to improve the multiplex Geniom system for detection and classification of known and unknown pathogens.
|
|
|
|
 |
|
"Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer"
Date: November 19, 2008
Client: QIAGEN
|
|
|
|
 |
|
"In-Q-Tel Invests in Febit" - Wade Roush
Date: November 19, 2008
Client: febit
Summary: febit, a Heidelberg, Germany-based maker of automated, microfluidic gene and RNA sequencing devices with laboratories in Lexington, MA, said today that In-Q-Tel, the venture wing of the U.S. intelligence community, has made a strategic investment in the company. The size of the investment was not disclosed, but In-Q-Tel's investments usually range between $1 million and $3 million, and are earmarked specifically for R&D in areas of interest to U.S. civilian and defense intelligence agencies.
|
|
|
|
 |
|
"FDA Advisory Committee Provides Opinion On Oritavancin For The Treatment of Complicated Skin and Skin Structure Infections"
Date: November 19, 2008
Client: Targanta Therapeutics
|
|
|
|
|
|
Date: November 18, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, of Lausanne, Switzerland, and Pharmaleads SAS, of Paris, entered into an exclusive licensing agreement for the development, registration and commercialization of Debio 0827, also called PL37, which is about to enter Phase I trials. The molecule is the first in a new class of painkillers targeting chronic pain conditions, primarily neuropathic pain, the firms said.
|
|
|
|
|
|
"Debiopharm and Pharmaleads sign licensing agreement"
Date: November 18, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, a global biopharmaceutical company, and Pharmaleads, a drug discovery and early development company, have signed an exclusive license agreement for the development, registration and commercialization of a small molecule called Debio 0827 or PL37, about to enter Phase I clinical trials.
|
|
|
|
|
|
"Debiopharm and Pharmaleads sign licensing agreement"
Date: November 18, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, a global biopharmaceutical company, and Pharmaleads, a drug discovery and early development company, have signed an exclusive license agreement for the development, registration and commercialization of a small molecule called Debio 0827 or PL37, about to enter Phase I clinical trials.
|
|
|
|
 |
|
"Debiopharm and Pharmaleads sign licensing agreement"
Date: November 17, 2008
Client: Debiopharm Group
Summary: Debiopharm and Pharmaleads SAS ink exclusive license agreement for the development, registration and commercialization of small molecule Debio 0827 or PL37 about to enter phase I clinical trials.
|
|
|
|
 |
|
"New Antibiotics Take Aim at Staph's Rise" - Jennifer Corbett Dooren
Date: November 17, 2008
Client: Targanta Therapeutics
Summary: A Food and Drug Administration advisory panel this week will consider three proposed antibiotics designed to treat serious skin infections, including some caused by a type of staph bacterium resistant to many antibiotics. The bacterium -- methicillin-resistant staph aureus, or MRSA -- has sparked concern as the super bug has moved into community settings like schools and locker rooms in recent years after once being largely confined to hospital settings. On Wednesday the panel is expected to vote on Theravance Inc.'s telavancin and Targanta Therapeutics Corp.'s oritavancin before considering iclaprim by Swiss biotech company Arpida Ltd. Thursday.
|
|
|
|
|
|
"Targanta Announces Posting of Briefing Documents For Review of FDA Anti-Infective Drugs Advisory Committee Meeting For Oritavancin"
Date: November 17, 2008
Client: Targanta Therapeutics
|
|
|
|
|
|
"Vical Executive Alain Rolland Named AAPS Fellow"
Date: November 17, 2008
Client: Vical
|
|
|
|
|
|
Date: November 17, 2008
Client: Debiopharm Group
Summary: Debiopharm and Pharmaleads SAS ink exclusive license agreement for the development, registration and commercialization of small molecule Debio 0827 or PL37 about to enter phase I clinical trials.
|
|
|
|
|
|
"Pharmaleads to Assist with Development of Debiopharm's Chronic Pain Therapeutic"
Date: November 17, 2008
Client: Debiopharm Group
Summary: Debiopharm and Pharmaleads inked an exclusive license agreement for the development, registration, and commercialization of Debio 0827 or PL37, a small molecule about to enter Phase I trials. Debio 0827 is in a new class of painkillers that could be used in the treatment of chronic pain conditions, primarily in neuropathic pain.
|
|
|
|
|
|
"Debiopharm, Pharmaleads sign license agreement for Debio 0827 or PL37"
Date: November 17, 2008
Client: Debiopharm Group
Summary: Switzerland-headquartered biopharmaceutical development company Debiopharm Group and drug discovery and early development company Pharmaleads SAS said today (17 November) that they have signed an exclusive license agreement for the development, registration and commercialisation of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials.
|
|
|
|
|
|
"Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions."
Date: November 17, 2008
Client: Debiopharm Group
|
|
|
|
|
|
Date: November 17, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, of Lausanne, Switzerland, said its new drug application for the six-month formulation of Trelstar (triptorelin pamoate) was accepted for filing by the FDA.
|
|
|
|
 |
|
"Endothelial Cell-Coated Stent Has Markedly Low Restenosis Rate" - Martha Kerr
Date: November 14, 2008
Client: OrbusNeich
Summary: A vascular stent that attracts endothelial progenitor cells (EPCs), which in turn form a functional endothelial cell lining inside the stent, has restenosis rates below 10% at one year, Dutch researchers announced here at the American Heart Association's Scientific Sessions 2008. Dr. Margo Klomp of the Academic Medical Center at the University of Amsterdam, the Netherlands reported one-year outcomes in 257 patients treated with the Genous EPC-capturing stent.
|
|
|
|
 |
|
"Fractional flow reserve guided PCI results in better outcomes- FAME investigators"
Date: November 14, 2008
Client: Radi Medical Systems
Summary: Results of the FAME (Fractional Flow Reserve Versus Angiography for Multi-vessel Evaluation) trial presented recently at the TCT 2008 suggests that routine measurement of fractional flow reserve (FFR) during PCI reduces adverse outcomes in patients with multivessel disease compared to conventional angiography guided angioplasty.
|
|
|
|
 |
|
"FDA Accepts Watson's, Debiopharm's Filing for Six-Month Formulation of Trelstar" - Gaelle Marinoni
Date: November 14, 2008
Client: Debiopharm Group
Summary: U.S. generic and specialty pharma firm Watson Pharmaceuticals and Swiss biopharmaceutical company Debiopharm have announced that their New Drug Application (NDA) for a 24-week formulation of oncology drug Trelstar (triptorelin pamoate) will be reviewed by the U.S. FDA in the palliative treatment of locally-advanced or metastatic prostate cancer.
|
|
|
|
 |
|
"Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer"
Date: November 14, 2008
Client: Debiopharm Group
Summary: Debiopharm Group, a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar® (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA).
|
|
|
|
|
|
"US FDA accepts Debiopharm's Trelstar NDA for filing"
Date: November 14, 2008
Client: Debiopharm Group
Summary: Swiss drugmaker Debiopharm says that its New Drug Application for the six-month formulation of Trelstar (triptorelin pamoate) has been accepted for filing by the US Food and Drug Administration. The agent is a luteinizing hormone-releasing hormone agonist for locally-advanced or metastatic prostate cancer that, once approved, will be sold by Watson Pharmaceuticals.
|
|
|
|
|
|
"Researchers Say Identification of Women with HPV Types 16, 18 and 45 Could Improve Early Intervention to Stop Cervical Cancer"
Date: November 14, 2008
Client: QIAGEN
|
|
|
|
 |
|
"Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated"
Date: November 13, 2008
Client: Ambrx
|
|
|
|
|
|
"Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference"
Date: November 13, 2008
Client: Anadys Pharmaceuticals
|
|
|
|
 |
|
"Approval sought for prostate cancer drug" - Jack Katzaneck
Date: November 13, 2008
Client: Debiopharm Group
Summary: Watson Pharmaceuticals Inc. will seek approval for a new drug that helps treat advanced prostate cancer, Trelstar, which reduces the flow of testosterone in men with prostate cancer. Trelstar was developed by Debiopharm Group.
|
|
|
|
|
|
"Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer"
Date: November 14, 2008
Client: Debiopharm Group
|
|
|
|
 |
|
"Treating rheumatoid arthritis with DMARDs and biologics" - By William E. Fogler, Ph.D.
Date: Fall 2008
Client: EntreMed
Summary: Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical utility and demonstrate attenuation in the disease progression of RA.
|
|
|
|
|
|
"Targanta Reports Third-Quarter 2008 Financial Results"
Date: November 12, 2008
Client: Targanta Therapeutics
|
|
|
|
|
|
"EntreMed Reports Clinical Program Progress and Company Update"
Date: November 12, 2008
Client: EntreMed
|
|
|
|
|
|
"Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial"
Date: November 12, 2008
Client: Vical
|
|
|
|
 |
|
"Antibody-coated stent eliminates need for blood thinners, study says"
Date: November 12, 2008
Client: OrbusNeich
Summary: Genous, an antibody-coated stent from OrbusNeich, was able to hold arteries open and allowed patients to forgo the use of anti-clotting drugs, according to a study presented Tuesday at an American Heart Association meeting. Genous is designed to gather progenitor cells to promote the growth of arterial tissue and as an alternative to drug-coated stents.
|
|
|
|
 |
|
"Antibody-coated stent eliminates need for blood thinners, study says"
Date: November 12, 2008
Client: OrbusNeich
Summary: Genous, an antibody-coated stent from OrbusNeich, was able to hold arteries open and allowed patients to forgo the use of anti-clotting drugs, according to a study presented Tuesday at an American Heart Association meeting. Genous is designed to gather progenitor cells to promote the growth of arterial tissue and as an alternative to drug-coated stents.
|
|
|
|
 |
|
"Human-Tissue Coating Helps Stent Work Without Blood Thinners" - Alex Nussbaum
Date: November 11, 2008
Client: OrbusNeich
Summary: A heart stent that coats itself with human tissue kept arteries open without patients needing to take anti-clotting medications, a study found. The stent, made by closely held OrbusNeich, offers an alternative to drug-coated devices made by Johnson & Johnson, Abbott Laboratories and Boston Scientific Inc., the lead author of the research said. Patients using those products also must take anti-clotting medicines for a year, but some patients cannot tolerate these medicines, for whom Genous is a good alternative.
|
|
|
|
 |
|
"Cell-coated stents as effective as drug-eluting, require less meds"
Date: November 11, 2008
Client: OrbusNeich
Summary: A new endothelial progenitor cell-capturing (EPC) stent that entices artery-lining cells to coat it works as well or better than drug-eluting stents (DES) in keeping arteries open in coronary heart disease patients, according to two research studies presented Tuesday at the American Heart Association (AHA) Scientific Sessions. The EPC stent is coated with an antibody that binds endothelial progenitor cells circulating in the blood. A number of smaller, randomized studies have shown that the stent is effective in carefully selected patients.
|
|
|
|
 |
|
"Interim data from 'real-world' registry backs use of Genous" - Elizabeth Cairns
Date: November 11, 2008
Summary: Genous, the antibody-coated stent developed by OrbusNeich, could provide a safer alternative to drug-eluting stents (DESs), trial results suggest. Interim 12-month data from the 5,000-patient e-HEALING registry were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2008 meeting held in Washington, D.C., last month. David Camp, vice-president of corporate development at OrbusNeich, speaks about the Genous stent and supporting data.
|
|
|
|
 |
|
"New Type of Stent Shows Promise" - Amanda Gardner
Date: November 11, 2008
Client: OrbusNeich
Summary: A new generation of stents shows promise in avoiding the late-onset problems that have plagued drug-eluting stents in patients with heart disease, researchers say. The tiny mesh tubes that are stents are intended to prop open narrowed arteries, but this new stent works in a novel way. It is coated with an antibody that provokes cells lining artery walls to migrate to and cover the stent, thus speeding the healing process and keeping arteries open longer.
|
|
|
|
 |
|
"Cell-coated stent as effective as drug-coated ones but needs less meds"
Date: November 11, 2008
Client: OrbusNeich
Summary: A stent that entices artery-lining cells to coat it works as well or better than drug-eluting stents in keeping arteries open in coronary heart disease patients, according to two research studies presented at the American Heart Association's Scientific Sessions 2008. The new endothelial progenitor cell-capturing (EPC) stent is coated with an antibody that binds endothelial progenitor cells circulating in the blood. A number of smaller, randomized studies have shown that the stent is effective in carefully selected patients.
|
|
|
|
 |
|
"OrbusNeich heart stent's sales rising "
Date: November 11, 2008
Client: OrbusNeich
Summary: A heart stent that coats itself with human tissue kept arteries open without patients needing to take anti-clotting medications, a study found. The stent, made by OrbusNeich, offers an alternative to drug-coated devices made by Johnson & Johnson, Abbott Laboratories and Boston Scientific Inc., said Sigmund Silber, who is lead author of the research and a cardiologist in Munich. In Europe, where the stent was approved in 2006, it has captured as much as 15 percent of sales, the company said.
|
|
|
|
|
|
"Cougar Biotechnology to Present at Lazard Capital Markets 5th Annual Healthcare Conference"
Date: November 11, 2008
Client: Cougar Biotechnology
|
|
|
|
|
|
"QIAGEN Reports Strong Third Quarter 2008 Results"
Date: November 10, 2008
Client: QIAGEN
|
|
|
|
|
|
"QIAGEN Introduces CE-marked Molecular Assay for the Cancer Biomarker K-ras"
Date: November 10, 2008
Client: QIAGEN
|
|
|
|
 |
|
"Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure"
Date: November 10, 2008
Client: Corthera
|
|
|
|
|
|
"Cougar Biotechnology Reports Third Quarter 2008 Financial Results"
Date: November 10, 2008
Client: Cougar Biotechnology
|
|
|
|
|
|
"EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial"
Date: November 10, 2008
Client: EntreMed
|
|
|
|
 |
|
"EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial"
Date: November 10, 2008
Client: EntreMed
Summary: EntreMed has met the primary endpoint for the efficacy portion of the open label Phase 1/2 study of MKC-1 in combination with pemetrexed (Alimta®) in non-small cell lung cancer patients.
|
|
|
|
|
|
"OrbusNeich to present e-HEALING interim analysis at AHA Scientific Sessions 2008"
Date: November 7, 2008
Client: OrbusNeich
Summary: OrbusNeich, a Hong Kong-based company which provides products to interventional cardiologists, announced today that it will present an interim analysis of 12-month patient subset data from e-HEALING, a global post-marketing surveillance registry of OrbusNeich's Genous Bio-engineered R stent, at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans.
|
|
|
|
 |
|
"Radi highlights importance of FFR in accurately obtaining stenosis measurements"
Date: November 7, 2008
Client: Radi Medical Systems
Summary: Radi Medical Systems has reported data from a randomised study, called FAME, that compares the use of fractional flow reserve (FFR) technology with angiography for improving the outcomes of patients with multi-vessel coronary artery disease (M
|
|
|
|
|
|
"EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference"
Date: November 7, 2008
Client: EntreMed
|
|
|
|
 |
|
"Interim Analysis of Data from e-HEALING Registry of OrbusNeich's Genous™ Bio-engineered R stent™ to be Presented at AHA Scientific Sessions 2008"
Date: November 7, 2008
Client: OrbusNeich
|
|
|
|
|
|
"EntreMed Reports Third Quarter 2008 Financial Results"
Date: November 6, 2008
Client: EntreMed
|
|
|
|
|
|
"QIAGEN and Institute for Animal Health Enter Partnership in Bluetongue Testing"
Date: November 6, 2008
Client: QIAGEN
|
|
|
|
|
|
"U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant"
Date: November 6, 2008
Client: Vical
|
|
|
|
|
|
"Targanta Therapeutics To Present At November 2008 Investor Conferences"
Date: November 5, 2008
Client: Targanta Therapeutics
|
|
|
|
|
|
"Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Program"
Date: November 5, 2008
Client: Vical
|
|
|
|
|
|
"Telaprevir Takes Center Stage as New HCV Approaches Advance" - Trista Morrison
Date: November 4, 2008
Client: GlobeImmune
Summary: New data on emerging drugs for the treatment of hepatitis C virus (HCV) were presented at the annual meeting of the American Association for the Study of Liver Disease (AASLD), including GlobeImmune Inc.'s immunotherapy GI-5005. The drug combines HCV antigens with a yeast-based delivery system, and initial Phase II data demonstrated a 2.6-fold improvement in rapid viral response at four weeks in treatment-naïve HCV patients with high viral loads at baseline who received GI-5005 plus standard of care, compared to standard of care alone.
|
|
|
|
|
|
"Vical to Present at Upcoming Investor Conferences"
Date: November 5, 2008
Client: Vical
|
|
|
|
|
|
"GlobeImmune reports promising results from Phase II hepatitis trial"
Date: November 5, 2008
Client: GlobeImmune
Summary: GlobeImmune released four-week Phase II clinical trial data showing GI-5005, the company's hepatitis C virus targeted molecular immunogen, doubled viral clearance overall and in all major subgroups and doubled the rapid virologic response rate in naive patients with high viral load.
|
|
|
|
|
|
"Sanvar® (Debio 8609) for esophageal variceal bleeding - Debiopharm submits response to the FDA"
Date: November 4, 2008
Client: Debiopharm Group
|
|
|
|
|
|
"GlobeImmune reports promising results from Phase II hepatitis trial"
Date: November 4, 2008
Client: GlobeImmune
Summary: Data from a four-week Phase II clinical trial showed that GI-5005 doubled viral clearance overall and in all major subgroups and doubled the rapid virologic response rate in naïve patients with high viral load.
|
|
|
|
|
|
"Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference"
Date: November 4, 2008
Client: Anadys Pharmaceuticals
|
|
|
|
|
|
|
Date: November 4, 2008
Client: EntreMed
Summary: EntreMed published preclinical results for 2ME2 (Panzem or 2-methoxyestradiol) in rheumatoid arthritis demonstrating daily oral administration of 2ME2 suppresses both clinical and radiographic indicators of joint inflammation and damage, including soft tissue swelling and bone erosion.
|
|
|
|
|
|
"Cougar Biotechnology to Present at Rodman & Renshaw 10th Annual Healthcare Conference"
Date: November 5, 2008
Client: Cougar Biotechnology
|
|
|
|
|
|
Date: November 3, 2008
Client: GlobeImmune
Summary: Early data from a Phase II trial GlobeImmune's HCV drug GI-5005 show that the drug doubled viral clearance overall and doubled the rapid virologic response rate in naïve patients with high viral load.
|
|
|
|
|
|
"Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models"
Date: November 3, 2008
Client: EntreMed
|
|
|
|
 |
|
"PCI: Fraktionierte Flussrate liefert bessere Ergebnisse" - Jochen Aumiller
Date: November 3, 2008
Client: Radi Medical Systems
Summary: Die klinischen Ergebnisse bei Mehrgefäßerkrankung werden signifikant verbessert, wenn im Rahmen der Angioplastie auch die fraktionierte Flussrate (FFR) ermittelt wird: Letalität oder Reinfarktrate waren um 35% reduziert, wenn sich die Interventionalisten nicht nur auf die Angiografieergebnisse verließen, sondern gleichzeitig die FFR berücksichtigten. Das ist die Kernbotschaft von FAME (Fractional Flow Reserve versus Angiography for Guiding PCI in Patients with Multivessel Coronary Artery Disease study).
|
|
|
|
|
|
"EntreMed's compound shows positive preclinical results for RA treatment"
Date: November 3, 2008
Client: EntreMed
Summary: Results from treatment studies in a preclinical model of established RA demonstrated that daily oral administration of 2ME2 suppressed both clinical and radiographic indicators of joint inflammation and damage, including soft tissue swelling and bone erosion.
|
|
|
|
 |
|
"EntreMed Publishes Preclinical Results For 2ME2 In Rheumatoid Arthritis - Quick Facts"
Date: November 3, 2008
Client: EntreMed
Summary: EntreMed Inc. (ENMD: News ) published the preclinical results for 2ME2 or Panzem or 2- methoxyestradiol in rheumatoid arthritis, in the November 2008 issue of the Journal of Rheumatology.
|
|
|
|
|
|
"Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008"
Date: November 3, 2008
Client: Corthera
|
|
|
|
|
|
"Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers"
Date: November 1, 2008
Client: Anadys Pharmaceuticals
|
|
|
|
 |
|
"GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial"
Date: November 1, 2008
Client: GlobeImmune
|
|
|
|
 |
|
"MicroRNA and Silencing RNA"
Date: November 2008
Client: febit
Summary: This article looks at the applications of MicroRNAs (miRNAs) and silencing RNA (siRNA) in studying diseases. Matthew Huentelman, Associate Investigator in the Neurobehavioral Research Unit at the Translational Genomics Research Institute (TGen) in Phoenix, AZ, is interested in the genetics of human neurological diseases, including neurodegenerative and neurobehavioral disorders. Noting that miRNA work is "showing signs of maturing as a fi eld," he has been using technology from febit (Heidelberg, Germany) to prepare customizable microarrays to investigate copy number changes associated with diseases of interest.
|
